Search Our Scientific Publications & Authors

Allergy 2022 Jul 1. Epub 2022 Jul 1.

Department of Respiratory Sciences, Leicester NIHR BRC, Institute for Lung Health, University of Leicester, Leicester, UK.

Background: In T2-mediated severe asthma, biologic therapies such as mepolizumab, are increasingly used to control disease. Current biomarkers can indicate adequate suppression of T2 inflammation, but it is unclear whether they provide information about airway microbial composition. We investigated the relationships between current T2 biomarkers and microbial profiles, characteristics associated with a Proteobacteria microbial profile and the effects of mepolizumab on airway ecology. Read More

Allergy 2022 Jul 1. Epub 2022 Jul 1.

Department of Allergy, Instituto de Investigacion Sanitaria Princesa (IP), Hospital Universitario de la Princesa, Madrid, Spain.

Allergy 2022 Jul 1. Epub 2022 Jul 1.

Laboratory of Inflammatory Skin Diseases, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Allergy 2022 Jun 30. Epub 2022 Jun 30.

Grup d'Immunologia Translacional, Departament de Biologia Cel·lular, Fisiologia i Immunologia, Facultat de Biologia, Universitat de Barcelona (UB), Parc Científic de Barcelona (PCB), Barcelona, Spain.

Allergy 2022 Jul;77(7):2264-2265

Allergy and Lung Health Unit, Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Vic., Australia.

Allergy 2022 Jul;77(7):2269-2270

Department of Dermatology, and Laboratory of Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Allergy 2022 Jul;77(7):2268

Department of Life Sciences and Public Health, Post-Graduate School of Pediatrics, Policlinico Gemelli Universitary Foundation IRCCS, Catholic University of Sacre Hearth, Rome, Italy.

Allergy 2022 Jul;77(7):1943-1949

Allergy 2022 Jul;77(7):2262-2263

Infectious Diseases Group, Murdoch Children's Research Institute, Parkville, VIC, Australia.

Allergy 2022 Jul;77(7):2266-2267

Allergy Research Group, Instituto de Investigación Biomédica de Málaga-IBIMA, Málaga, Spain.

Allergy 2022 Jun 24. Epub 2022 Jun 24.

NOVA Institute for Health, 1407 Fleet Street, Baltimore, MD 21231, USA.

Planetary health provides a perspective of ecological interdependence that connects the health and vitality of individuals, communities, and Earth's natural systems. It includes the social, political, and economic ecosystems that influence both individuals and whole societies. In an era of interconnected grand challenges threatening health of all systems at all scales, planetary health provides a framework for cross-sectoral collaboration and unified systems approaches to solutions. Read More

Allergy 2022 Jun 22. Epub 2022 Jun 22.

Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, CA, USA.

The incidence of food allergy (FA) has continued to rise over the last several decades, posing significant burdens on health and quality of life. Significant strides into the advancement of FA diagnosis, prevention, and treatment have been made in recent years. In an effort to lower reliance on resource-intensive food challenges, the field has continued work toward the development of highly sensitive and specific assays capable of high-throughput analysis to assist in the diagnosis FA. Read More

Allergy 2022 Jun 22. Epub 2022 Jun 22.

Department of Otolaryngology, Head and Neck Surgery, Universitätsmedizin Mainz, Mainz, Germany.

Allergy 2022 Jun 20. Epub 2022 Jun 20.

Immunological Biotechnology, Department of Biological and Chemical Engineering, Aarhus University, Aarhus, Denmark.

Background: Immune responses to N-glycan structures from allergens and parasites are often associated with pronounced, high affinity IgE reactivities. Cross-reactive carbohydrate determinants (CCDs) are constituted by modified N-glycan core structures and represent the most frequently recognized epitopes in allergic immune responses. Although recently accepted as potentially allergenic epitopes, the biological and clinical relevance as well as structural and functional characteristics of CCD-specific antibodies remain elusive. Read More

Allergy 2022 Jun 20. Epub 2022 Jun 20.

Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Technische Universität München.

Systemic allergic reactions to vaccines are very rare. In this study we assessed the management and outcome of suspected SARS-CoV-2 vaccine hypersensitivity. 334 individuals underwent an allergy work up regarding SARS-CoV-2 vaccination (group A: 115 individuals suspected to be at increased risk for vaccine related reactions before vaccination and group B: 219 patients with reactions after COVID vaccination). Read More

Allergy 2022 Jun 18. Epub 2022 Jun 18.

Department of Otolaryngology-Head and Neck Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Allergy 2022 Jun 18. Epub 2022 Jun 18.

Laboratory of Immune Regulation, Immunology Frontier Research Center, Osaka University, Osaka, Japan.

Allergy 2022 Jun 17. Epub 2022 Jun 17.

Sorbonne Université, Inserm, Childhood Genetic Disorders and Département de Génétique Médicale, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital Armand-Trousseau, Paris, France.

Allergy 2022 Jun 17. Epub 2022 Jun 17.

Institute of Applied Molecular Medicine Nemesio Diaz (IMMAND), Department of Basic Medical Sciences, Facultad de Medicina, Universidad San Pablo CEU, CEU Universities, Madrid, Spain.

Allergic diseases and asthma are heterogenous chronic inflammatory conditions with several distinct complex endotypes. Both environmental and genetic factors can influence the development and progression of allergy. Complex pathogenetic pathways observed in allergic disorders present a challenge in patient management and successful targeted treatment strategies. Read More

Allergy 2022 Jun 16. Epub 2022 Jun 16.

National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

Allergy 2022 Jun 16. Epub 2022 Jun 16.

Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands.

Allergy 2022 Jun 14. Epub 2022 Jun 14.

Department of Infection and Immunity, Luxembourg Institute of Health, Esch-sur-Alzette, Luxembourg.

Background: Food challenges carry a burden of safety, effort and resources. Clinical reactivity and presentation, such as thresholds and symptoms, are considered challenging to predict ex vivo.

Aims: To identify changes of peripheral immune signatures during oral food challenges (OFC) that correlate with the clinical outcome in patients with peanut allergy (PA). Read More

Arerugi 2022 ;71(4):341

Arerugi 2022 ;71(4):338-340

Arerugi 2022 ;71(4):336-337

Arerugi 2022 ;71(4):334-335

Arerugi 2022 ;71(4):328-333

Department of Pediatrics, Kasugai Municipal Hospital.

We describe here the case of a 7-year-old male patient with Stevens-Johnson syndrome (SJS), which was suspected to be caused by treatment with tipepidine hibenzate (Asverin). The day after taking tipepidine hibenzate and L-carbocysteine (Carbocysteine DS) for relief of a cold, he began presenting with the following symptoms: fever above 38°C, wheezing, and decreased oxygen saturation. Two days later, mucous membrane rashes, such as erosions on the lips, eye mucosa, vulva, and blisters on the trunk appeared, and SJS was thus diagnosed. Read More

Arerugi 2022 ;71(4):321-327

Department of Infectious Diseases and Respiratory Medicine, Fukushima Medical University Aizu Medical Center.

A-55-year-old man who have been working in a Sake (Japanese rice wine) brewer for 27 years, came to the outpatient clinic because cough, dyspnea, and wheeze gradually worsen. These symptoms occurred immediately after exposure to Aspergillus oryzae in the brewing process since age 43. A dust mask was required to reduce these symptoms, but that work was interrupted by exacerbation of these symptoms. Read More

Arerugi 2022 ;71(4):313-320

Hanamizuki Clinic.

Background: Ten percent efinaconazole nail solution (EFCZ solution) is a new topical triazole antifungal drug, and we sometimes encounter patients with allergic contact dermatitis (ACD) caused by EFCZ solution in our outpatient clinic. However, no previous reports have summarized the patch test (PT) results obtained for individual ingredients in several patients with EFCZ solution-induced ACD.

Objectives: This study aimed to 1) confirm the causative agent of EFCZ solution-induced ACD based on PT of individual ingredients and 2) analyze the optimal concentration and vehicle for such PT on the basis of previous studies. Read More

Arerugi 2022 ;71(4):301-312

Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences.